Scisparc

Scisparc Pre-Tax Margin

The Pre-Tax Profit Margin of Scisparc (SPRC) as of Nov 12, 2026 is -1,467.76 %. In the previous year, Pre-Tax Profit Margin was -573.20 % — a change of 156.06% (lower).

Pre-Tax Margin

-1,467.76 %

YoY

156.06%

Last updated:

Pre-Tax Profit Margin of Scisparc is 2025 -1,467.76 % . Pre-Tax Profit Margin of Scisparc was 2024 -573.20 % . It decreases by 156.06% lower compared to the previous year.

The Scisparc Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-1,075.06 USD
Jan 1, 2019
-899.40 USD
Jan 1, 2020
-642.73 USD
Jan 1, 2021
-541.53 USD
Jan 1, 2022
-191.39 USD
Jan 1, 2023
-203.58 USD
Jan 1, 2024
-573.20 USD
Jan 1, 2025
-1,467.76 USD
The Scisparc Pre-Tax Margin history
YEARPre-Tax MarginYoY
-1,467.76 %+156.06%
-573.20 %+181.56%
-203.58 %+6.37%
-191.39 %-64.66%
-541.53 %-15.74%
-642.73 %-28.54%
-899.40 %-16.34%
-1,075.06 %-16.15%
-1,282.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

Pre-Tax Profit Margin of Scisparc is -1,467.76 % in 2025.

Pre-Tax Profit Margin of Scisparc changed from -573.20 % to -1,467.76 %, representing a 156.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Scisparc since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Scisparc with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Scisparc

All Key Metrics — Scisparc